Scopus Eşleşmesi Bulundu
9
Atıf
16
Cilt
S10-S18
Sayfa
Özet
Transfusional iron overload remains a serious problem in alloHSCT setting. Liver is among the most common organs that iron accumulate. The degree of hepatic iron content might be associated with poorer survival in alloHSCT recipients. Aim Iron overload results in increased infection, venous-oclusive disease and hepatic dysfunction in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. Liver is one of the most common sites of iron overload. Patients and Methods A total of 50 alloHSCT recipients that underwent liver biopsy in Erciyes Stem Cell Transplantation Hospital, Erciyes University, between 2004 and 2011 were enrolled in the study. The liver biopsy specimens have been obtained from the archives of Erciyes University, Department of Pathology and stainned for iron content. Results The mean age was found 34 ± 11 years. For median overall survival (OS); 53 months (min-max: 41-65) in patients with grade 0, 55 months (min-max: 47-64) in patients with grade 1, in patients with grade 2 patients 25.4 months (11.5-39.4 ), grade 3 patients 29.3 months (min-max: 12.3-46.3) and grade 4 patients 2.6 months (min-max: 2.0-3.3). Overall survival was correlated with the degree of liver iron content and it was statistically significant in Kaplan-Meier analysis (P < .001). Disease-free survival was found (DFS); grade 0 patients 47.1 months (min-max: 32.0-62.0), grade 1 patients 36.9 months (min-max: 21.0-65.0), grade 2 patients 23.5 months (min-max: 12.0-59.0), grade 3 patients 27.4 months (min-max: 5.3-59.3) and grade 4 patients 2.6 months (min-max: 2.0-3.0). For DFS; it was negatively correlated with the degree of liver iron content nevertheless; it was not was statistically significant in Kaplan-Meier analysis (P = .093).Hepatic iron overload might be associated with poor survival in patients with transfusional iron overload that underwent alloHSCT. Conclusion Hepatic iron content might be associated with poorer prognosis in patients with iron overload that underwent alloHSCT.
Web of Science Eşleşmesi Bulundu
9
WoS Atıf
16
Cilt
Article, Meeting
Belge Türü
Kaynak: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
· s. S10-S18
Anahtar Kelimeler (WoS)
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 9.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2016 yılı verileri
Clinical Lymphoma, Myeloma and Leukemia
Q2
SJR Quartile
0,772
SJR Skoru
68
H-Index
Kategoriler: Hematology (Q2) · Oncology (Q2) · Cancer Research (Q3)
Alanlar: Biochemistry, Genetics and Molecular Biology · Medicine
Ülke: United States
· Elsevier Inc.
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Anahtar Kelimeler
WoS |
Bir kelimeye tıklayıp ilgili kaynaktaki yayınları görün.
Makale Bilgileri
Dergi
Clinical Lymphoma Myeloma and Leukemia
ISSN
21522650
Yıl
2016
/ 8. ay
Cilt / Sayı
16
/ 1
Sayfalar
10 – 18
Makale Türü
Özgün Makale
Hakemlik
Hakemli
Endeks
SCI-Expanded
Yayın Dili
İngilizce
Kapsam
Uluslararası
Toplam Yazar
8 kişi
Erişim Türü
Elektronik
Alan
Sağlık Bilimleri Temel Alanı-
İç Hastalıkları
YÖKSİS Yazar Kaydı
Yazar Adı
ŞIVGIN SERDAR,BALDANE SÜLEYMAN,DENİZ KEMAL,ZARARSIZ GÖKMEN,KAYNAR LEYLAGÜL,ÇETİN MUSTAFA,ÜNAL ALİ,ESER BÜLENT
YÖKSİS ID
2146847